#COMPPARE early results: in localized #ProstateCancer, #proton therapy vs #IMRT showed no sig difference in pt-reported bowel urgency/frequency, ≥G2 GI toxicity, or 3-year biochemical control. Longer follow-up needed for late toxicity/long term outcomes #ASCO2026
🚨 PROTEUS: perioperative apalutamide moves into high-risk localized #prostatecancer
Just out in @NEJM
🧬 2109 men w/ high-risk localized or locally advanced PCa randomized to ADT + apalutamide vs ADT + placebo around radical prostatectomy.
🎯 Both stated primary endpoints met.
⚠️ But the trial deserves nuance. Thread 🧵
#ASCO26 @ASCO@PCF_Science
Clear cell RCC sheds low levels of ctDNA, but positivity and ctDNA dynamics are relevant in the adjuvant setting @DrChoueiri#ASCO26. This analysis is with an exome based personalised technique and shows a lack of sensitivity (5-8% ctDNA+ve rate vs 40% radiological relapse rate) but good specificity (almost all ctDNA +ves relapse). Whole genome ctDNA analysis should work work better. There is a future for ctDNA in renal cancer, we’re just not quite there yet IMO.
Retrospective real-world clinicogenomic study in @Nature
5893 pts with mCRPC
37% HRR pathogenic variants.
13% BRCA1/2.
389 received olaparib:
BRCA2: median OS 17.5 mo
BRCA1: 8.1 mo
HR 2.23 (P=0.008)
BRCA1 clearly worse.
Within BRCA2, subtype defines benefit ⚠️
BRCA2 loss: median OS 24.3 mo
HR 0.42 (P<0.001)
This is intra-BRCA functional heterogeneity ‼️
Not all BRCA alterations are biologically or therapeutically equivalent.
https://t.co/EVyVPFf7HN @OncoAlert
This is a massively important trial —you rarely see this. Important for the field and for the region. It's time to reflect on PD1 dosing… !
Bravo @VanitaNoronha et al!
@OncoAlert@JCO_ASCO@TataMemorial@ASCO
Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma.
https://t.co/A5unScwF2i
JUST IN: 2 Belzutifan (HIF2 inhibitor) phase III trials POSTIVE for Primary Endpoint in Renal Cell Carcinoma: LITEPSPAK022 (adjuvant) + LITESPARK011 (metastatic, post PD1).
BIG NEWS for GU Oncology + Kidney Cancer patients!
https://t.co/poOKpXP5nJ
https://t.co/wP9gu8ppLI
2/2 this becomes standard of care here. Questions-How would this perform in a cisplatin eligible population? Better? Can ctDNA help? How many cycles are needed? B15 & VOLGA can help here.Finally, bladder sparing trials are needed to address the need for surgery @OncoAlert#ESMO25
1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery
The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS & OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again @OncoAlert
🚨 New data at #ESMO25!
Outcomes with enfortumab vedotin + pembrolizumab (EV/P) in metastatic urothelial carcinoma harboring FGFR3 or ERBB2 alterations.
Presented by @MichalSternsch & @dr_aggen — Poster #3102P
📍Memorial Sloan Kettering Cancer Center | #MSKCC | @@MSK_DeptofMed #BladderCancer #Oncology
RAMPART #ESMO25 adjuvant durvalumab/tremelimumab delays DFS in adjuvant RCC vs supportive care. This is confusing as ipi/nivo did not hit DFS. Durvalumab monotherapy data will help on component parts. Benefit seems confined to good risk. Adjuvant pembro has OS here. @OncoAlert
🚨 New in European Urology:
Consolidative surgery after #EnfortumabVedotin +/– ICI in advanced urothelial carcinoma:
✅ 82% downstaging
✅ 43% ypT0N0
✅ 79% stopped systemic therapy
✅ 89% DFS in curative group
📄 https://t.co/Yd52YZKRNk
#BladderCancer#Immunotherapy#Urology